A prospective study to evaluate the efficacy and safety of vitamin E and levocarnitine prophylaxis against doxorubicin-induced cardiotoxicity in adult breast cancer patients.
Autor: | Moustafa, Iman, Connolly, Catherine, Anis, Malik, Mustafa, Hani, Oosthuizen, Frasia, Viljoen, Michelle |
---|---|
Předmět: |
THERAPEUTIC use of vitamin E
COMBINATION drug therapy PATIENT safety CARNITINE BREAST tumors STATISTICAL sampling TREATMENT effectiveness RANDOMIZED controlled trials PEPTIDE hormones LONGITUDINAL method CANCER chemotherapy CREATINE kinase CARDIOTOXICITY DOXORUBICIN CANCER patient psychology COMPARATIVE studies EVALUATION ADULTS |
Zdroj: | Journal of Oncology Pharmacy Practice; Mar2024, Vol. 30 Issue 2, p354-366, 13p |
Abstrakt: | Background: Doxorubicin induces acute and chronic cardiotoxicity. This study is aimed to evaluate the efficacy and safety of vitamin E and levocarnitine (EL) as cardioprotective agents against acute doxorubicin cardiotoxicity in female adult breast cancer patients. Methods: A prospective, randomized controlled study was conducted in patients treated with doxorubicin and cyclophosphamide (AC). Patients were randomly assigned to EL plus AC or AC alone for the duration of 4 cycles. Cardiac enzymes (B-type natriuretic peptide, creatine kinase, troponin I (Trop)) and cardiac events were monitored during treatment to evaluate the cardioprotective efficacy of EL. Results: Seventy-four patients were recruited and received four cycles of chemotherapy. The intervention group (n = 35) showed a significant reduction in both the B-type natriuretic peptide and creatine kinase cardiac enzymes compared to the control group (n = 39). The median (IQR) change for BNP was 0.80 (0.00–4.00) for IG versus 1.80 (0.40–3.60) for CG groups (p < 0.001); creatine kinase was −0.08 (−0.25–0.05) for IG versus 0.20 (0.05–0.50) for CG (p < 0.001). The addition of EL decreased the cardiac events by 24.2% (p = 0.02). All adverse events were tolerable and manageable. Conclusion: This study supports the addition of EL as prophylaxis against acute doxorubicin cardiotoxicity and it was also very well tolerated by a majority of the patients. The co-administration of EL at higher doxorubicin (240 mg/m2) dose should be further investigated. [ABSTRACT FROM AUTHOR] |
Databáze: | Complementary Index |
Externí odkaz: |